SCHEMBL6901115

SCHEMBL6901115

O=C(O)CNC(=O)c1ccc(C(=O)O)o1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.69
ALDH1A1 P00352 6/20 0.67
TDP1 Q9NUW8 3/20 0.67
TSHR P16473 2/20 0.67
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 6/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
APEX1 P27695 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HIF1A Q16665 1/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
RAB9A P51151 2/20 0.45
NPC1 O15118 2/20 0.45
USP5 P45974 1/20 0.44
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5717558 0.83 ALDH1A1 (0.73) POLBALDH1A1TDP1TSHRLMNA
SCHEMBL12999968 0.81 L3MBTL1 (0.71) POLBALDH1A1TDP1TSHRLMNA
SCHEMBL7074467 0.80 ALDH1A1 (1.00) POLBALDH1A1TDP1TSHRLMNA
SCHEMBL13402907 0.79 POLB (0.61) POLBALDH1A1TDP1TSHRLMNA
SCHEMBL17019790 0.78 TDP1 (0.50) POLBALDH1A1TDP1L3MBTL1SMN1; SMN2
SCHEMBL11904537 0.76 TDP1 (0.61) POLBALDH1A1TDP1HPGDMEN1
SCHEMBL38726 0.76 TDP1 (0.61) POLBALDH1A1TDP1HPGDMEN1
SCHEMBL21129198 0.75 POLB (0.56) POLBALDH1A1TDP1TSHRLMNA
Succinic Acid SCHEMBL16507130 0.74 TDP1 (0.56) POLBALDH1A1TDP1LMNAL3MBTL1
SCHEMBL13892780 0.74 POLB (0.55) POLBALDH1A1TDP1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6746678-B1 Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments SECANT PHARMA, LLC 2004-06-08 US disclosed
EP-0572560-B1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 2003-01-29 EP disclosed
EP-0707446-A4 PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 2001-01-10 EP disclosed
US-5668117-A NERVOUS SYSTEM DISORDERS USING AROMATIC ACID COMPOUNDS SECANT PHARMA, LLC 1997-09-16 US disclosed
EP-0707446-A1 PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1996-04-24 EP disclosed
EP-0572560-A4 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. SHAPIRO HOWARD K (US) 1995-04-26 EP disclosed
WO-1995001096-A1 PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1995-01-12 WO disclosed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP disclosed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO disclosed